Company intelligence / Profile preview

Andover Eye Institute

Andover, Massachusetts, United Statesaeiclinical.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

AEI does not develop its own drugs but serves as a high-throughput site for industry-sponsored clinical trials. Over its history: "AEI has supported over 85 drug approvals over 45 years, with up to 15 studies annually, leveraging next-generation technology including scalable AI models."

Therapeutic areas: ImmunologyDermatologyOphthalmology
Modalities: Small moleculeBiologicDevice
Industry: Contract Research Organization

Drug pipeline

1 asset

CWT-f-002

Completed

Indications: Dry eye disease

Partnerships

Major pharmaceutical companies developing ophthalmic therapiesOra Clinical

Beyond the preview

Go deeper on Andover Eye Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andover Eye Institute.

Explore the full profile